These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24664646)

  • 1. Canadian approval sought for controversial pain drug.
    Brown C
    CMAJ; 2014 May; 186(8):571. PubMed ID: 24664646
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA chief defends Zohydro approval as US states rebel.
    McCarthy M
    BMJ; 2014 Apr; 348():g2939. PubMed ID: 24764572
    [No Abstract]   [Full Text] [Related]  

  • 3. Chronic pain, addiction, and Zohydro.
    Olsen Y; Sharfstein JM
    N Engl J Med; 2014 May; 370(22):2061-3. PubMed ID: 24758596
    [No Abstract]   [Full Text] [Related]  

  • 4. Zohydro approval by food and drug administration: controversial or frightening?
    Manchikanti L; Atluri S; Candido KD; Boswell MV; Simopoulos TT; Grider JS; Falco FJ; Hirsch JA
    Pain Physician; 2014; 17(4):E437-50. PubMed ID: 25054396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approval of New Opioid Raises Concerns.
    Aschenbrenner DS
    Am J Nurs; 2019 Feb; 119(2):20-21. PubMed ID: 30681473
    [No Abstract]   [Full Text] [Related]  

  • 6. Extended-release hydrocodone (Zohydro) for pain.
    Med Lett Drugs Ther; 2014 Jun; 56(1444):45-6. PubMed ID: 24933087
    [No Abstract]   [Full Text] [Related]  

  • 7. REMS; red tape, or a remedy for opioid abuse?
    Porada S
    J Fam Pract; 2011 Sep; 60(9 Suppl):S55-62. PubMed ID: 22442761
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA Approval of Extended-Release Oxycodone for Children With Severe Pain.
    Yang YT; Chen B; Bennett CL
    Pediatrics; 2016 May; 137(5):. PubMed ID: 27244829
    [No Abstract]   [Full Text] [Related]  

  • 9. Both Urgency and Balance Needed in Addressing Opioid Epidemic: A Report From the National Academies of Sciences, Engineering, and Medicine.
    Bonnie RJ; Kesselheim AS; Clark DJ
    JAMA; 2017 Aug; 318(5):423-424. PubMed ID: 28715551
    [No Abstract]   [Full Text] [Related]  

  • 10. US bill would force FDA to withdraw approval of new pain drug Zohydro.
    McCarthy M
    BMJ; 2014 Mar; 348():g2195. PubMed ID: 24637611
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment with an Extended-Release Hydrocodone Tablet Formulated with Abuse-Deterrence Technology: A 12-month Open-label Study in Patients with Chronic Pain.
    Hale ME; Zimmerman TR; Ma Y; Malamut R
    Pain Pract; 2017 Feb; 17(2):229-238. PubMed ID: 26857424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preserving beneficence.
    Peppin J
    Pain Med; 2013 May; 14(5):619. PubMed ID: 23581845
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA is urged to reverse its approval of new pain drug Zohydro ER.
    McCarthy M
    BMJ; 2014 Mar; 348():g1894. PubMed ID: 24591422
    [No Abstract]   [Full Text] [Related]  

  • 14. Primum non nocere.
    Franklin GM
    Pain Med; 2013 May; 14(5):617-8. PubMed ID: 23581809
    [No Abstract]   [Full Text] [Related]  

  • 15. A pendulum swings awry: seeking the middle ground on opioid prescribing for chronic non-cancer pain.
    Schatman ME; Darnall BD
    Pain Med; 2013 May; 14(5):617. PubMed ID: 23581746
    [No Abstract]   [Full Text] [Related]  

  • 16. DEA reschedules hydrocodone combination products.
    Pergolizzi JV
    Pain Pract; 2015 Feb; 15(2):95-7. PubMed ID: 25639283
    [No Abstract]   [Full Text] [Related]  

  • 17. Combating the increase in opioid misuse.
    Nolan W; Gannon R
    Conn Med; 2013 Sep; 77(8):495-8. PubMed ID: 24156180
    [No Abstract]   [Full Text] [Related]  

  • 18. Interpreting labels of abuse-deterrent opioid analgesics.
    Webster LR
    J Opioid Manag; 2017; 13(6):415-423. PubMed ID: 29308588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential.
    Hale ME; Ma Y; Malamut R
    J Opioid Manag; 2016; 12(2):139-47. PubMed ID: 27194199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydrocodone bitartrate for chronic pain.
    Manchikanti L; Atluri S; Kaye AM; Kaye AD
    Drugs Today (Barc); 2015 Jul; 51(7):415-27. PubMed ID: 26261844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.